EVOK News and Press, Evoke Pharma Inc. From 01/14/21

Evoke Pharma (EVOK) has priced its public offering of 5M common shares at $2.50/share, for estimated gross proceeds of $12.5M.Underwriter's over-allotment is an additional 750K shares. Net proceeds will be used for working capital and general corporate purposes.Laidlaw & Company is acting...

SOLANA BEACH, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that it has priced an underwritten public offering of 5,000,000 shares of its...

Evoke Pharma (EVOK) dropped 5.1% in after-hours after it announced plans to offer and sell shares of its common stock in a firm commitment underwritten public offering; underwriters granted 45-day option to purchase an additional 15% of the shares.Actual size, terms of the offe...

SOLANA BEACH, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that it intends to offer and sell shares of its common stock in a “fir...

Evoke Pharma shares jump ([[EVOK]] +14.4%) after it announces positive findings from a market research study for its diabetic gastroparesis treatment Gimoti.Evoke through its marketing partner, EVERSANA, conducted an ATU (Awareness, Trial, and Usage) study, a quantitative survey to measure ph...

Gainers: Acorda Therapeutics (ACOR) +45%, NuCana (NCNA) +26%, Synlogic (SYBX) +24%, Evoke Pharma (EVOK) +23%, Tiziana Life Sciences (TLSA) +14%.Losers: Zomedica (ZOM) -26%, Forward Pharma (FWP) -15%, Provention Bio (PRVB) -14%, Acutu...

SOLANA BEACH, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (“Evoke” or the “Company”) (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced positive findings from...

SOLANA BEACH, Calif. and CHICAGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, a leading provider of global commercial services to the life science indu...

SOLANA BEACH, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer R.Ph., President and Chief Executive Officer, and Matt D’Onofrio, ...

Evoke Pharma (NASDAQ: EVOK ) has entered into a sales and distribution agreement with Eversana Life Science Services, as contemplated by the commercial services agreement dated January 2020. More news on: Evoke Pharma, Inc., Healthcare stocks news, Read more ...